M

Moleculin Biotech

MBRX

2.24000
USD
-0.85
(-27.51%)
Market Closed
Volume
540
EPS
0
Div Yield
0
P/E
-0
Market Cap
7,225,099
Related Instruments
A
ABUS
0.03500
(0.93%)
3.80500 USD
A
AKTX
-0.45000
(-10.66%)
3.77000 USD
B
BPTH
-0.06000
(-3.80%)
1.52000 USD
C
CTXR
-0.00050
(-0.06%)
0.90610 USD
C
CVM
0.02000
(1.77%)
1.15000 USD
I
INO
-0.670
(-6.28%)
10.000 USD
T
TCON
0.00000
(0.00%)
1.45000 USD
T
TNXP
0.00960
(1.92%)
0.51050 USD
News

Title: Moleculin Biotech

Sector: Healthcare
Industry: Biotechnology
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.